
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is poised for success with strong financials, promising study results, and strategic collaborations. With a diversified pipeline targeting critical pathways in cancer, the company has the potential for significant growth in the market. Additionally, their focus on partnerships for commercialization and combination treatments show a commitment to increasing the effectiveness of their treatments and potentially expanding their market reach.
Bears say
Verastem is facing challenges in its RAMP 205 trial, with positive but mixed results from its phase 1b/2a expansion cohort in metastatic pancreatic cancer showing a 52% cORR, 68% 6-month PFS rate, and 86% 6-month OS rate, but with still limited follow-up on mPFS/mOS. The company's management is pinning its hopes on potential collaborations and the potential role of avutometinib/defactinib in metastatic pancreatic cancer, but the assumed launch of these drugs in 2025 with a high cost of therapy and limited potential peak penetration rates does not bode well for the company's financial outlook in the near term.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares